167 related articles for article (PubMed ID: 21519338)
1. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.
Bigos KL; Bies RR; Pollock BG; Lowy JJ; Zhang F; Weinberger DR
Mol Psychiatry; 2011 Jun; 16(6):620-5. PubMed ID: 21519338
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of the antipsychotic drug olanzapine by CYP3A43.
Zhao J; Machalz D; Liu S; Wolf CA; Wolber G; Parr MK; Bureik M
Xenobiotica; 2022 Apr; 52(4):413-425. PubMed ID: 35582917
[TBL] [Abstract][Full Text] [Related]
3. No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.
Söderberg MM; Molden E; Dahl ML
Pharmacogenet Genomics; 2014 May; 24(5):272-5. PubMed ID: 24595013
[TBL] [Abstract][Full Text] [Related]
4. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
[TBL] [Abstract][Full Text] [Related]
5. Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine.
Cashman JR; Zhang J; Nelson MR; Braun A
Drug Metab Lett; 2008 Apr; 2(2):100-14. PubMed ID: 19356079
[TBL] [Abstract][Full Text] [Related]
6. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.
Tiwari AK; Brandl EJ; Weber C; Likhodi O; Zai CC; Hahn MK; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
J Clin Psychopharmacol; 2013 Feb; 33(1):11-7. PubMed ID: 23277265
[TBL] [Abstract][Full Text] [Related]
7. Sex, race, and smoking impact olanzapine exposure.
Bigos KL; Pollock BG; Coley KC; Miller DD; Marder SR; Aravagiri M; Kirshner MA; Schneider LS; Bies RR
J Clin Pharmacol; 2008 Feb; 48(2):157-65. PubMed ID: 18199892
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.
Citrome L; Stauffer VL; Chen L; Kinon BJ; Kurtz DL; Jacobson JG; Bergstrom RF
J Clin Psychopharmacol; 2009 Jun; 29(3):278-83. PubMed ID: 19440083
[TBL] [Abstract][Full Text] [Related]
9. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in CYP3A43 is associated with response to antipsychotic medication.
Brandl EJ; Chowdhury NI; Tiwari AK; Lett TA; Meltzer HY; Kennedy JL; Müller DJ
J Neural Transm (Vienna); 2015 Jan; 122(1):29-34. PubMed ID: 25150845
[TBL] [Abstract][Full Text] [Related]
11. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients.
Tiwari AK; Zai CC; Meltzer HY; Lieberman JA; Müller DJ; Kennedy JL
Hum Psychopharmacol; 2010 Apr; 25(3):253-9. PubMed ID: 20373477
[TBL] [Abstract][Full Text] [Related]
12. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.
Ellingrod VL; Bishop JR; Moline J; Lin YC; Miller DD
Psychopharmacol Bull; 2007; 40(1):57-62. PubMed ID: 17285096
[TBL] [Abstract][Full Text] [Related]
13. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Ramsey TL; Brennan MD
Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
[TBL] [Abstract][Full Text] [Related]
15. Variables associated with high olanzapine dosing in a state hospital.
Botts S; Littrell R; de Leon J
J Clin Psychiatry; 2004 Aug; 65(8):1138-43. PubMed ID: 15323601
[TBL] [Abstract][Full Text] [Related]
16. Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Fijal BA; Stauffer VL; Kinon BJ; Conley RR; Hoffmann VP; Witte MM; Zhao F; Houston JP
J Clin Psychiatry; 2012 Mar; 73(3):367-71. PubMed ID: 21813073
[TBL] [Abstract][Full Text] [Related]
17. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
[TBL] [Abstract][Full Text] [Related]
18. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
Stone A; Ratnasinghe LD; Emerson GL; Modali R; Lehman T; Runnells G; Carroll A; Carter W; Barnhart S; Rasheed AA; Greene G; Johnson DE; Ambrosone CB; Kadlubar FF; Lang NP
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1257-61. PubMed ID: 15894682
[TBL] [Abstract][Full Text] [Related]
19. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Meyer JM; Rosenblatt LC; Kim E; Baker RA; Whitehead R
J Clin Psychiatry; 2009 Mar; 70(3):318-25. PubMed ID: 19192469
[TBL] [Abstract][Full Text] [Related]
20. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3.
Okubo M; Narita M; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):83-92. PubMed ID: 26856397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
